All In Biotech

Drug Trial Radar · NCT06009094

Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Jul 27, 2023

Primary completion

May 23, 2024

Study completion May 23, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single center, randomized, double-blind, Vehicle controlled,, single and multiple dose clinical study.

Conditions

  • Atopic Dermatitis

Interventions

  • VC005Drug

    VC005 group with Local topical application

  • VC005 PlaceboDrug

    VC005 Placebo group with Local topical application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Plasma Concentration (Cmax)Time frame: Day2,Day 4,Day17,Day31

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences Hospital of Skin Disease

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.